Company: STAA
Filing Date: 2025-06-25
Form Type: 8-K
Source: 0000950170-25-089733
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-06-25
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 25, 2025, STAAR Surgical Company (the “ Company”) announced that its Board of Directors (the “ Board”) appointed Deborah Andrews as Chief Financial Officer of the Company, effective June 25, 2025 (the “ Effective Date”). In this role, Ms. Andrews will also serve as the Company’s principal financial officer and principal accounting officer under the rules and regulations of the Securities and Exchange Commission. Ms. Andrews has served as the Company’s Interim Chief Financial Officer since March 2025.

Ms. Andrews, age 67, retired from the Company in 2020, after more than two decades at the Company. She most recently served as the Company’s Chief Financial Officer, from September 2017 until June 2020, after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as the Company’s Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Since April 2014, Ms. Andrews has served on the Board of Directors of Lineage Cell Therapeutics, a clinical stage biotechnology company focused in the field of regenerative medicine. She currently serves as its Audit Committee Chair and has previously served as its Compensation Committee Chair. Ms. Andrews spent three years from 1991 to 1994 as an accountant for KPMG. Ms. Andrews holds a B. S. degree in accounting from California State University at San Bernardino.

Ms. Andrews has no family relationship to the Company nor to any of its directors or executive officers, and there are no transactions in which Ms. Andrews has an interest requiring disclosure under Item 404(a) of Regulation S-K. There is no arrangement or understanding between Ms. Andrews and any other person pursuant to which Ms. Andrews was appointed as an officer of the Company.

In connection with Ms. Andrews’ appointment as Chief Financial Officer, Ms. Andrews accepted an offer letter pursuant to which she will receive base salary at an annual rate of $495,000 and will be eligible to participate in the Company’s annual cash bonus program with a target bonus of 55% of her base salary. In addition, the Board approved the grant of an equity award with a grant date fair value of